The role of atypical antipsychotic drugs in schizophrenia

Psychiatric Bulletin

Volumn 25, Issue 8, 2001, Pages 281-282

  Kerwin, R W ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; ZOTEPINE;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG USE; EDITORIAL; HUMAN; PRESCRIPTION; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0034872145     PISSN: 09556036     EISSN: None     Source Type: Journal    
DOI: 10.1192/pb.25.8.281     Document Type: Editorial

References (9)

1. "Nobody ever expects the Spanish Inquisition" (Python, 1991)
2. Choosing antipsychotic drugs in schizophrenia. A personal view
3. Delay to antipsychotic medication in schizophrenia. Impact on symptomatology and clinical course of the illness
4. Evidence biased psychiatry?
5. National Schizophrenia Fellowship on treatment guidelines
6. An essay on the use of new antipsychotics (with commentary response by T.R.E. Barnes)
7. Time course and biological correlates of treatment response to first episode schizophrenia
8. First-line atypical antipsychotics for schizophrenia are appropriate - With psychological interventions
9. Prescribing in schizophrenia. Evaluating the effect of introducing a new treatment protocol